Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026)
Verano Holdings' (VRNO) quarterly Total Non-Current Liabilities came in at $902.9 million in Q1 2026, up 5.02% year-on-year from $859.7 million in Q1 2025, and little changed on a QoQ basis from $899.0 million in Q4 2025.
Verano Holdings (VRNO) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Total Non-Current Liabilities data on file, last reported at $902.9 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 5.02% year-over-year to $902.9 million in Q1 2026; TTM through Mar 2026 was $902.9 million, a 5.02% increase from a year earlier, with the FY2025 full-year figure at $899.0 million, up 7.0% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $902.9 million, roughly flat from $899.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for VRNO reached as high as $902.9 million in Q1 2026 and fell as low as $469.5 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $736.3 million across 5 years, with a median of $680.7 million in 2023.
- Across the five-year window, Total Non-Current Liabilities surged 43.17% in 2023 and retreated 4.02% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $667.9 million in 2022, then declined by 0.21% to $666.5 million in 2023, then gained by 26.06% to $840.2 million in 2024, then gained by 7.0% to $899.0 million in 2025, then advanced by 0.44% to $902.9 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $902.9 million in Q1 2026, $899.0 million in Q4 2025, and $897.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 902.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 902.87 Mn |
| Dec 31, 2025 | 898.95 Mn |
| Sep 30, 2025 | 897.85 Mn |
| Jun 30, 2025 | 868.42 Mn |
| Mar 31, 2025 | 859.73 Mn |
| Dec 31, 2024 | 840.17 Mn |
| Sep 30, 2024 | 661.59 Mn |
| Jun 30, 2024 | 657.07 Mn |
| Mar 31, 2024 | 661.13 Mn |
| Dec 31, 2023 | 666.48 Mn |
| Sep 30, 2023 | 689.32 Mn |
| Jun 30, 2023 | 672.14 Mn |
| Mar 31, 2023 | 669.11 Mn |
| Dec 31, 2022 | 667.86 Mn |
| Sep 30, 2022 | 698.54 Mn |
| Jun 30, 2022 | 469.47 Mn |
| Dec 31, 2021 | 596.33 Mn |